Data from the first Phase 2 clinical trial of CERE-120 later this year in Lancet Neurology (online October 21, 2010 published published.. Said ‘The nanotube surface of the sensor by detecting the change in shape of the DNA, as it has responded to the presence of the target ions,’Heller.Co-authors of the paper with Strano and Heller are student Esther Jeng and students Tsun – Kwan Yeung, Brittany Martinez, Anthonie Moll and Joseph Gastala.The work was funded by the National Science Foundation.James E. KloeppelCeregene heralds a new Phase 2b Trial Of CERE-120 for ParkinsonCeregene, a biopharmaceutical company, announced that enrollment started in a new double-blind sham surgery – controlled Phase 2b study evaluating CERE-120 in Parkinson’s patients.

Their discovery opens the door to new kinds of optical sensors and biomarkers that exploit the unique properties of nanoparticles in living systems. ‘This is the first nanotube-based sensor that can detect analytes at the subcellular level,’said Michael Strano, a professor of chemical and biomolecular engineering at Illinois and corresponding author of a paper said on the 27th January issue of Science magazine appears. ‘We have also for the first time, show that a subtle rearrangement of an adsorbed biomolecules detected directly from a carbon nanotube. Continue reading

The reasons for conducting this study is based on unexpected positive results from the recently completed Phase II trial in Dry Eye, which, due to a decrease of intraocular pressure in patients treated with CF101.

Glaucoma is one leading cause of blindness and currently affects about 90 million patients worldwide from the disease. The main treatments today consist of eye drops, which is not easy to use for patients regularly and thus increase compliance challenges. Therefore a need for a market exists systemic, orally administered drug such as CF101. The market today is $ 5.5 billion and is estimated $ 8.4 billion $ 8.4 billion in 2012. Continue reading

The largest studies may have reached different conclusions because neither included a control group of uninfected people, Peter Sklar and Henry Masur said in an editorial in the journal.She suggested that the weight of evidence available that people who used under the antiretroviral drugs now to fend off HIV are more likely to have a heart attack appears. But the extent of this risk is unknown. However, the are one of the wonders of the last decades have been, they said. Survival ‘ to work, but we need to stem the toxic effects that have the potential to reduce the quality and duration of patients ‘ long run. ‘.

The eye, like other parts of the body it may infected by histoplasmosis, may asymptomatic for several years.Ryan Prall, assistant professor of ophthalmology at the Eugene and Marilyn Glick Eye Institute said:’The fungus may in the layer of the eye behind the retina histoplasmosis spots or scars cause submit These usually usually significant. ‘Ocular histoplasmosis is usually rare, but here in Indiana , a considerable number of people have the spots caused by the scar tissue ‘ Dr. Explains a member of the Indiana University School of Medicine faculty. He said:. Continue reading

An ischemic stroke caused by a blood clot and is the most common type of stroke. ‘The average age of stroke in people with HIV was in the 50s, which suggests much lower than that of people without HIV This finding, that can HIV or HIV treatments are to stroke to stroke occurrence Did Ovbiagele. ‘In fact, a possible explanation is the increasing use of combination antiretroviral therapy medications in HIV-infected people. While these therapies have life expectancy life expectancy, they can be the presence of risk factors that increase associated with stroke. Another possibility is that a longer exposure to HIV as a result of greater survival, even at low viral load may allow the virus to increase stroke risk..

Contact: Rachel Champeau 310-794-2270 Natalie Waugh , up to three times more likely to have a stroke compared to those not affected with HIV are. The study is in the 19 January 2011, online edition of neurologists, the medical journal of the American Academy of Neurology published. ‘Our findings show that stroke hospitalizations in the United States by seven per cent lower in the general population in the past decade while stroke hospitalizations for people with HIV by 67 per cent,’said Bruce Ovbiagele, professor of neuroscience at University of California, San Diego and a member of the American Academy of Neurology.. Continue reading

Page 3 of 3123